Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-11-12 Report Publication Anno…
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma: Invitation to Q3 2024 Results Presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Lytix Biopharma: Invitation to Q3 2024 Results Presentation' and explicitly states that the company 'will release its third quarter 2024 financial results on Tuesday, 19 November 2024.' It then provides details for a live webcast presentation to discuss these results, including the date, time, and Q&A instructions. This is not the actual financial report (which would be an IR or ER), but rather an announcement about the upcoming release event and presentation. According to Rule 2 (The 'MENU VS MEAL' Rule), if a document announces the publication or presentation of a report, it should be classified as a Report Publication Announcement (RPA).
2024-11-12 English
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Regulatory Filings Classification · 99% confidence The document is a press release from Lytix Biopharma announcing that the first patient has been treated in a new Phase II clinical trial (NeoLIPA) evaluating their drug candidate LTX-315 for early-stage melanoma. This type of announcement, detailing clinical trial progress, drug development updates, and market potential, is characteristic of communications aimed at investors and the public regarding ongoing operations and pipeline status, but it is not a formal regulatory filing like a 10-K, a formal earnings release (ER), or a comprehensive interim report (IR). It is a specific operational update. Since there is no category for 'Clinical Trial Update' or 'Press Release', the most appropriate general category for significant, non-financial, non-governance operational news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous regulatory/corporate announcements not covered by the specific codes. However, given the content is a detailed operational update about a clinical trial, it is often classified as a general corporate announcement. Comparing the options, it is not a financial report (10-K, IR, ER), a governance document (DEF 14A, CGR), or a transaction notice (DIV, POS, DIRS). It is a specific announcement about the company's core business activity (drug development). In many databases, such detailed operational news releases default to the general regulatory/announcement category.
2024-11-06 English
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Regulatory Filings Classification · 95% confidence The document announces a specific operational event: the treatment of the first patient in a new Phase II clinical trial (NeoLIPA) for the drug candidate LTX-315 in early-stage melanoma patients. It includes details about the trial design, endpoints, market potential, and contact information. This type of announcement, focusing on clinical trial progress and operational milestones rather than comprehensive financial results (10-K, IR) or management changes (MANG), is characteristic of general corporate or operational updates often categorized under Regulatory Filings (RNS) if no other specific category fits. Since it is not a formal financial report, earnings release, or management discussion, RNS serves as the most appropriate general regulatory/operational announcement category.
2024-11-06 English
Lytix Biopharma – Oppdatering fra lisensieringspartner Verrica Pharmaceuticals
Legal Proceedings Report Classification · 99% confidence The document is a short press release from Lytix Biopharma referencing and summarizing the Q3 financial results and leadership changes announced by its licensing partner, Verrica Pharmaceuticals, on November 4, 2024. It also mentions that Lytix Biopharma will present its own Q3 results on November 19. Since this document is short (3237 chars) and primarily serves to inform the market about an external earnings announcement and an upcoming internal one, it fits the description of an Earnings Release (ER) or, more accurately given the context of referencing another company's results, a general regulatory announcement. However, the core content relates to financial performance reporting for a period (Q3). If Lytix's own results are coming later (Nov 19), this announcement acts as a preliminary update or a reference to the partner's results which impacts Lytix. Given the mention of 'pressemeldingen for 3. kvartal' (Q3 press release) and the announcement of Lytix's own results presentation date, the closest fit among the specific codes is 'ER' (Earnings Release) or 'RPA' (Report Publication Announcement) because it announces the context of upcoming results. Since it is summarizing the partner's ER and announcing Lytix's own results presentation, and it is not the full report itself, 'RPA' (Report Publication Announcement) is a strong candidate, as it announces the publication/context of results. However, 'ER' is defined as the 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document contains key highlights (partner's results, leadership change, Lytix's upcoming presentation date). Given the context of financial reporting periods, ER is slightly more specific than RPA, but RPA fits the 'announcement of publication' aspect well. Since it is primarily an update referencing financial results, I will lean towards ER as it covers the financial period update, even if it's secondary information about the partner. If Lytix's own results are not yet released, this functions as a market update related to earnings. Given the ambiguity, and the fact that it is an update about financial results, ER is chosen, but RPA is a close second. I will select ER as it directly relates to the financial period results being discussed.
2024-11-05 Norwegian
Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals
M&A Activity Classification · 99% confidence The document is a brief update from Lytix Biopharma referencing an announcement made by its licensing partner, Verrica Pharmaceuticals. The key information shared includes Verrica's Q3 financial results announcement, a leadership transition (new CEO), and updates on clinical trials. The document itself is short (4203 characters) and primarily serves to relay news about another company's filings and internal changes. It mentions Verrica's Q3 announcement and Lytix's upcoming Q3 presentation. Since the text is an announcement referencing other corporate events, including management changes (new CEO) and financial results from a partner, it touches upon several categories. However, the most prominent new information specific to Lytix's direct communication is the mention of the new CEO at the partner company and the reference to the partner's financial results and leadership transition. The document also mentions Lytix's upcoming Q3 results presentation. Given the focus on management changes at the partner (Dr. Rieger appointed CEO) and the fact that Lytix is relaying this information, the 'Board/Management Information' (MANG) category is highly relevant, as is 'Earnings Release' (ER) due to the reference to Q3 results. Since this is an update *about* another company's management change and financial reporting, and it is not the full report itself, it functions as a general corporate announcement. Because it explicitly mentions a 'new management' appointment at the partner, MANG is a strong fit. If it were Lytix's own management change, MANG would be certain. Given the context of relaying partner news that includes management changes, MANG is the most specific fit among the options that cover corporate governance/personnel updates, even if secondary to the financial mention. However, since it is a brief update referencing partner financial results and management changes, and it is not a formal regulatory filing itself, it could also be RNS. Comparing MANG and ER: it mentions the ER but focuses on the management change as well. I will classify it as MANG because the appointment of a new CEO is a specific event highlighted alongside the financial update.
2024-11-05 English
Lytix Biopharma – Oppdatering fra lisensieringspartner Verrica Pharmaceuticals
Report Publication Announcement Classification · 99% confidence The document is a short update from Lytix Biopharma referencing a press release from its licensing partner, Verrica Pharmaceuticals, regarding Q3 financial results and a leadership transition (new CEO). It also mentions Lytix Biopharma's upcoming Q3 results presentation and provides details about the licensing agreement and ongoing clinical trials. Since the document itself is an announcement referencing the publication of another company's financial results and leadership changes, and it is very short (2695 chars), it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it specifically announces/references the publication of financial results and leadership changes, RPA is a strong candidate if it were announcing its own report, but since it is primarily an update referencing *another* company's earnings release and management change, and it is not a standard SEC form, the most appropriate general category for a brief, non-standard regulatory update referencing external events is RNS (Regulatory Filings/Miscellaneous Announcement). However, the content heavily features management changes (new CEO at Verrica, which affects Lytix's board) and references an Earnings Release (Verrica's Q3 report). Because it is a brief communication referencing external financial results and management changes, and not the full report itself, RNS is the safest fallback, although it touches upon elements of ER and MANG. Given the structure as a brief update referencing external news, RNS is selected as the best fit among the provided options for a non-standard, short communication.
2024-11-05 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.